Richard Fair, M.B.A., serves as President and Chief Executive Officer of Enliven Therapeutics Inc., a clinical-stage precision oncology company developing next-generation small molecule inhibitors for genetically defined cancer targets. With over 25 years of experience in the biopharmaceutical industry, Fair has built a distinguished career focused on business development, strategic partnerships, and advancing innovative therapies from discovery through commercialization. His leadership has been instrumental in navigating high-stakes transactions and fostering growth in oncology-focused biotech firms. Prior to joining Enliven in 2021, Fair held pivotal roles at several leading companies, including Chief Business Officer at Turning Point Therapeutics, where he spearheaded business development efforts culminating in the company's $4.1 billion acquisition by Bristol Myers Squibb in 2022. Earlier, as Vice President of Business Development at Array BioPharma, he contributed to transformative collaborations and the firm's eventual acquisition by Pfizer for $11.4 billion. His tenure also includes key positions at Oncothyreon Inc. and Genentech/Roche, where he honed expertise in licensing, alliances, and portfolio strategy, driving multiple value-creating deals in targeted therapies. At Enliven, Fair oversees the company's pipeline, including its lead candidate ELI-002 for mKRAS-driven cancers, and leads efforts to advance precision medicine solutions. A proven dealmaker and strategist, he holds an M.B.A. from the University of Washington Foster School of Business and a B.S. in Biology from the University of California, San Diego, blending scientific acumen with executive prowess to position Enliven for long-term success in oncology.